C. Kent Osborne

43.0k citations

173 papers · 25.4k indexed · 10 hit papers · h-index 79

Oncology top 0.05%
Molecular Biology top 0.2%
Cancer Research top 0.05%
Genetics top 0.05%
Pulmonary and Respiratory Medicine top 0.5%

Co-authors: Rachel Schiff Gary M. Clark D. Craig Allred Richard Elledge Susan G. Hilsenbeck Carlos L. Arteaga Grazia Arpino Gary C. Chamness
Topics: HER2/EGFR in Cancer Research (76 papers)Estrogen and related hormone effects (71 papers)Breast Cancer Treatment Studies (37 papers)
Cited by: Cancer Research Oncology Genetics
Journals: New England Journal of Medicine Proceedings of the National Academy of Sciences The Lancet
Partner nations: United States United Kingdom Italy

In The Last Decade

C. Kent Osborne

169 papers receiving 24.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer

1999 1.6k citations Jennet Harvey, Gary M. Clark et al. Journal of Clinical Oncology profile →
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy

2008 1.4k citations Michael T. Lewis, Jian Huang et al. JNCI Journal of the National Cancer Institute profile →
Tamoxifen in the Treatment of Breast Cancer

1998 1.0k citations C. Kent Osborne profile →
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

2014 936 citations Matthew D. Burstein, Anna Tsimelzon et al. Clinical Cancer Research profile →
Mechanisms of Endocrine Resistance in Breast Cancer

2010 877 citations C. Kent Osborne, Rachel Schiff Annual Review of Medicine profile →
Treatment of HER2-positive breast cancer: current status and future perspectives

2011 696 citations C. Kent Osborne et al. profile →
Association of p53 Protein Expression With Tumor Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer

1993 683 citations D. Craig Allred, Gary M. Clark et al. JNCI Journal of the National Cancer Institute profile →
Role of the Estrogen Receptor Coactivator AIB1 (SRC-3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer

2003 642 citations C. Kent Osborne, Gary C. Chamness et al. JNCI Journal of the National Cancer Institute profile →
The value of estrogen and progesterone receptors in the treatment of breast cancer

1980 579 citations C. Kent Osborne, William McGuire et al. profile →
Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

2003 565 citations Grazia Arpino, Richard Elledge et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by C. Kent Osborne

Since Specialization

Citations

This map shows the geographic impact of C. Kent Osborne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Kent Osborne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Kent Osborne more than expected).

Fields of papers citing papers by C. Kent Osborne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Kent Osborne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Kent Osborne. The network helps show where C. Kent Osborne may publish in the future.

Co-authorship network of co-authors of C. Kent Osborne

This figure shows the co-authorship network connecting the top 25 collaborators of C. Kent Osborne. A scholar is included among the top collaborators of C. Kent Osborne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Kent Osborne. C. Kent Osborne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis 2023 ·Clinical Cancer Research ·Grazia Arpino,Juan de la Haba-Rodríguez,Jean-Marc Ferrero,Sabino De Placido,C. Kent Osborne,Dirk Klingbiel,(unknown),(unknown),(unknown),Mothaffar F. Rimawi,(unknown)	25
2	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2–Positive and Hormone Receptor–Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial 2018 ·Journal of Clinical Oncology ·Mothaffar F. Rimawi,Jean-Marc Ferrero,Juan de la Haba-Rodríguez,Christopher Poole,Sabino De Placido,C. Kent Osborne,Roberto Hegg,Valerie Easton,(unknown),Grazia Arpino,(unknown)	142
3	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance 2016 ·Molecular Cancer Research ·Luca Malorni,Mario Giuliano,Ilenia Migliaccio,Tao Wang,Chad J. Creighton,Mathieu Lupien,Xiaoyong Fu,Susan G. Hilsenbeck,Nuala Healy,Carmine De Angelis,Abhijit Mazumdar,Meghana V. Trivedi,Suleiman Massarweh,Carolina Gutiérrez,Sabino De Placido,Rinath Jeselsohn,Myles Brown,Powel H. Brown,C. Kent Osborne,Rachel Schiff	31
4	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival 2016 ·Cancer Research ·Petra den Hollander,(unknown),Anna Tsimelzon,Jonathan H. Shepherd,Abhijit Mazumdar,Jamal Hill,Suzanne A.W. Fuqua,Jenny C. Chang,C. Kent Osborne,Susan G. Hilsenbeck,Gordon B. Mills,Powel H. Brown	70
5	Targeting HER2 for the Treatment of Breast Cancer 2015 ·Annual Review of Medicine ·Mothaffar F. Rimawi,Rachel Schiff,C. Kent Osborne	208
6	Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancerbreakdown → 2014 ·Clinical Cancer Research ·Matthew D. Burstein,Anna Tsimelzon,Graham M. Poage,Kyle R. Covington,Alejandro Contreras,Suzanne A.W. Fuqua,Michelle I. Savage,C. Kent Osborne,Susan G. Hilsenbeck,Jenny C. Chang,Gordon B. Mills,Ching C. Lau,Powel H. Brown	936
7	Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer 2013 ·The Breast ·Xiaoyong Fu,C. Kent Osborne,Rachel Schiff	64
8	Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006 2013 ·Journal of Clinical Oncology ·Mothaffar F. Rimawi,Ingrid A. Mayer,Andres Forero,Rita Nanda,Matthew P. Goetz,Angel Rodriguez,Anne C. Pavlick,Tao Wang,Susan G. Hilsenbeck,Carolina Gutiérrez,Rachel Schiff,C. Kent Osborne,Jenny C. Chang	187
9	Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up 2012 ·Breast Cancer Research and Treatment ·Luca Malorni,Priya B. Shetty,Carmine De Angelis,Susan G. Hilsenbeck,Mothaffar F. Rimawi,Richard Elledge,C. Kent Osborne,Sabino De Placido,Grazia Arpino	175
10	Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts 2010 ·Clinical Cancer Research ·Mothaffar F. Rimawi,Lisa Wiechmann,Yen-Chao Wang,Catherine Huang,Ilenia Migliaccio,Meng-Fen Wu,Carolina Gutiérrez,Susan G. Hilsenbeck,Grazia Arpino,Suleiman Massarweh,(unknown),(unknown),C. Kent Osborne,Rachel Schiff	66
11	Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice 2009 ·JNCI Journal of the National Cancer Institute ·Tracy E. Strecker,Qiang Shen,Yun Zhang,Jamal Hill,Yuxin Li,Chunyu Wang,Hee-Tae Kim,Tona M. Gilmer,K. Sexton,Susan G. Hilsenbeck,C. Kent Osborne,Powel H. Brown	41
12	Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function 2008 ·Cancer Research ·Suleiman Massarweh,C. Kent Osborne,Chad J. Creighton,Lanfang Qin,Anna Tsimelzon,Shixia Huang,Heidi L. Weiss,Mothaffar F. Rimawi,Rachel Schiff	375
13	Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts 2008 ·Cancer Research ·Chad J. Creighton,Suleiman Massarweh,Shixia Huang,Anna Tsimelzon,Susan G. Hilsenbeck,C. Kent Osborne,Jiang Shou,Luca Malorni,Rachel Schiff	101
14	Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapybreakdown → 2008 ·JNCI Journal of the National Cancer Institute ·(unknown),Michael T. Lewis,Jian Huang,Carolina Gutiérrez,C. Kent Osborne,(unknown),S. G. Hilsenbeck,Anne C. Pavlick,Xiaolei Zhang,Gary C. Chamness,Hiu Yung Wong,Jeffrey M. Rosen,Jenny C. Chang	1418
15	Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. 2003 ·PubMed ·Rachel Schiff,Suleiman Massarweh,Jiang Shou,C. Kent Osborne	250
16	Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancerbreakdown → 1999 ·Journal of Clinical Oncology ·Jennet Harvey,Gary M. Clark,C. Kent Osborne,D. Craig Allred	1630
17	HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. 1998 ·PubMed ·Richard Elledge,(unknown),Daniel R. Ciocca,R Pugh,D. Craig Allred,Gary M. Clark,(unknown),Peter M. Ravdin,Joe M. O’Sullivan,Silvana Martino,C. Kent Osborne	203
18	The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. 1994 ·The EMBO Journal ·D. L. Stein,Jian Wu,Suzanne A.W. Fuqua,(unknown),Vijay Yajnik,Peter D’Eustachio,John J. Moskow,Arthur M. Buchberg,C. Kent Osborne,Ben Margolis	206
19	Tumor Biologic Factors and Breast Cancer Prognosis Among White, Hispanic, and Black Women in the United States 1994 ·JNCI Journal of the National Cancer Institute ·Richard Elledge,Gary M. Clark,Gary C. Chamness,C. Kent Osborne	357
20	Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer 1992 ·Human Pathology ·D. Craig Allred,Gary M. Clark,Rafael Molina,Atul K. Tandon,Stuart J. Schnitt,Kennedy W. Gilchrist,C. Kent Osborne,Douglass C. Tormey,William McGuire	329

About C. Kent Osborne

C. Kent Osborne is a scholar working on Oncology, Cancer Research and Genetics, having authored 173 papers that have together received 25.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (76 papers), Estrogen and related hormone effects (71 papers) and Breast Cancer Treatment Studies (37 papers). The work is most often cited by research in Cancer Research (8.8k citations), Oncology (14.8k citations) and Genetics (8.7k citations). C. Kent Osborne has collaborated with scholars based in United States, United Kingdom and Italy. Frequent co-authors include Rachel Schiff, Gary M. Clark, D. Craig Allred, Richard Elledge, Susan G. Hilsenbeck, Carlos L. Arteaga, Grazia Arpino, Gary C. Chamness, Suzanne A.W. Fuqua and Jennet Harvey. Their work appears in journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact